stockportfolio.pro
Stocks / INCY vs VTRS
INCY vs VTRS
Incyte Corporation and Viatris Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Incyte Corporation (INCY) | Viatris Inc. (VTRS) | |
|---|---|---|
| Market cap | $20.4B | $19.0B |
| Revenue (latest FY) | $5.14B | $14.30B |
| Net income (latest FY) | $1.29B | $-3.51B |
| Revenue growth (5y CAGR) | 14.0% | 3.7% |
| Net margin | 25.0% | -24.6% |
| Return on equity | 24.9% | -23.9% |
| P/E ratio | 14.4 | — |
| Dividend yield | — | 2.9% |
| Profitable years (of last 10) | 8 | 4 |
| Positive free cash flow | — | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open INCY — free Open VTRS — freeFrequently asked questions
Which is bigger, INCY or VTRS?
Incyte Corporation is larger by market capitalization — $20.4B versus $19.0B.
Which grows faster, INCY or VTRS?
Over the last five fiscal years, Incyte Corporation grew revenue faster — 14.0%/yr versus 3.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.